NCT07549269

Brief Summary

Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used. However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
387

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2019

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

April 9, 2026

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 24, 2026

Completed
Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

5 years

First QC Date

April 9, 2026

Last Update Submit

April 17, 2026

Conditions

Esophageal Cancer

Keywords

ESCCNeoadjuvant therapyNab-Paclitaxel, Paclitaxel

Outcome Measures

Primary Outcomes (2)

  • PCR

    Pathological Complete Response

    Within 4 weeks after surgery

  • DFS

    disease-free survival

    From surgery to tumor progression or death

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This retrospective study included 1,163 ESCC patients who underwent esophagectomy at West China Hospital of Sichuan University between June 2019 and December 2024. After screening, 387 eligible patients were included.

You may qualify if:

  • Patients of any age with a histologically confirmed diagnosis of ESCC who were considered resectable or potentially resectable based on baseline assessment were eligible.

You may not qualify if:

  • Any untreated malignancy within the past five years (except fully treated cervical carcinoma in situ or basal/squamous cell skin cancer), receipt of other neoadjuvant treatments (chemotherapy, chemoradiotherapy, or chemoradiotherapy combined with immunotherapy), incomplete medical records, or refusal to participate in follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital

Chengdu, Sichuan, China

Location

MeSH Terms

Conditions

Esophageal Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

April 9, 2026

First Posted

April 24, 2026

Study Start

December 1, 2019

Primary Completion

December 1, 2024

Study Completion

April 1, 2026

Last Updated

April 24, 2026

Record last verified: 2026-04

Locations

CN(1)